Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Sep;14(3):456–458. doi: 10.1111/j.1365-2125.1982.tb02009.x

The effect of prolonged treatment with sulphinpyrazone on thromboxane A2 and prostacyclin in man.

L Viinikka, J Toivanen, O Ylikorkala
PMCID: PMC1427641  PMID: 6812610

Abstract

We studied the effect of 3 weeks' treatment with 4 x 200 mg of sulphinpyrazone daily (six healthy volunteers) on proaggregatory thromboxane A2 (TxA2) and antiaggregatory prostacyclin (PGI2). Platelet TxA2 production was evaluated by measuring its stable metabolite, immunoreactive thromboxane B2, from serum, and vessel wall PGI2 production by measuring its stable metabolite, immunoreactive 6-keto-prostaglandin F1 alpha in plasma. The TxA2 production (initially 209.0 +/- 27.1 ng/ml, mean +/- s.e. mean) decreased to about 30% from the second day of the treatment onwards, and it recovered in three days after the discontinuation of the treatment. PGI2 (initially 33.6 +/- 3.6 pg/ml) did not change. The shift of the balance between TxA2 and PGI2 to the dominance of antiaggregatory PGI2 during sulphinpyrazone treatment may be involved with the efficacy of the drug in the secondary prevention of myocardial infarction.

Full text

PDF
456

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coker S. J., Parratt J. R., Ledingham I. M., Zeitlin I. J. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature. 1981 May 28;291(5813):323–324. doi: 10.1038/291323a0. [DOI] [PubMed] [Google Scholar]
  2. Coker S. J., Parratt J. R. The effects of prostaglandins E2, F2 alpha, prostacyclin, flurbiprofen and aspirin on arrhythmias resulting from coronary artery ligation in anaesthetized rats. Br J Pharmacol. 1981 Sep;74(1):155–159. doi: 10.1111/j.1476-5381.1981.tb09968.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gordon J. L., Pearson J. D. Effects of sulphinpyrazone and aspirin on prostaglandin I2 (prostacyclin) synthesis by endothelial cells. Br J Pharmacol. 1978 Dec;64(4):481–483. doi: 10.1111/j.1476-5381.1978.tb17308.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Green L. H., Seroppian E., Handin R. I. Platelet activation during exercise-induced myocardial ischemia. N Engl J Med. 1980 Jan 24;302(4):193–197. doi: 10.1056/NEJM198001243020403. [DOI] [PubMed] [Google Scholar]
  5. Haerem J. W. Sudden coronary death: the occurrence of platelet aggregates in the epicardial arteries of man. Atherosclerosis. 1971 Nov-Dec;14(3):417–432. doi: 10.1016/0021-9150(71)90070-0. [DOI] [PubMed] [Google Scholar]
  6. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hirsh P. D., Hillis L. D., Campbell W. B., Firth B. G., Willerson J. T. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981 Mar 19;304(12):685–691. doi: 10.1056/NEJM198103193041201. [DOI] [PubMed] [Google Scholar]
  8. Kumpuris A. G., Luchi R. J., Waddell C. C., Miller R. R. Production of circulating platelet aggregates by exercise in coronary patients. Circulation. 1980 Jan;61(1):62–65. doi: 10.1161/01.cir.61.1.62. [DOI] [PubMed] [Google Scholar]
  9. Lewy R. I., Wiener L., Walinsky P., Lefer A. M., Silver M. J., Smith J. B. Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation. 1980 Jun;61(6):1165–1171. doi: 10.1161/01.cir.61.6.1165. [DOI] [PubMed] [Google Scholar]
  10. Livio M., Villa S., de Gaetano G. Long-lasting inhibition of platelet prostaglandin but normal vascular prostacyclin generation following sulphinpyrazone administration to rats. J Pharm Pharmacol. 1980 Oct;32(10):718–719. doi: 10.1111/j.2042-7158.1980.tb13049.x. [DOI] [PubMed] [Google Scholar]
  11. Lorenz R., Siess W., Weber P. C. Effects of very low versus standard dose acetyl salicylic acid, dipyridamole and sulfinpyrazone on platelet function and thromboxane formation in man. Eur J Pharmacol. 1981 Apr 9;70(4):511–518. doi: 10.1016/0014-2999(81)90362-9. [DOI] [PubMed] [Google Scholar]
  12. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  13. Moncada S., Vane J. R. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979 May 17;300(20):1142–1147. doi: 10.1056/NEJM197905173002006. [DOI] [PubMed] [Google Scholar]
  14. Moschos C. B., Escobinas A. J., Jorgensen O. B., Jr, Regan T. J. Effect of sulfinpyrazone on ventricular fibrillation during acute myocardial ischemia. Circulation. 1981 Jul;64(1):13–18. doi: 10.1161/01.cir.64.1.13. [DOI] [PubMed] [Google Scholar]
  15. Mustard J. F., Rowsell H. C., Smythe H. A., Senyi A., Murphy E. A. The effect of sulfinpyrazone on platelet economy and thrombus formation in rabbits. Blood. 1967 Jun;29(6):859–866. [PubMed] [Google Scholar]
  16. Neri Serneri G. G., Gensini G. F., Abbate R., Mugnaini C., Favilla S., Brunelli C., Chierchia S., Parodi O. Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: relationships to coronary pathoanatomy, risk factors, and clinical manifestations. Am Heart J. 1981 Feb;101(2):185–194. doi: 10.1016/0002-8703(81)90665-7. [DOI] [PubMed] [Google Scholar]
  17. SMYTHE H. A., OGRYZLO M. A., MURPHY E. A., MUSTARD J. F. THE EFFECT OF SULFINPYRAZONE (ANTURAN) ON PLATELET ECONOMY AND BLOOD COAGULATION IN MAN. Can Med Assoc J. 1965 Apr 10;92:818–821. [PMC free article] [PubMed] [Google Scholar]
  18. Smith E. F., 3rd, Lefer A. M., Smith J. B. Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Can J Physiol Pharmacol. 1980 Mar;58(3):294–300. doi: 10.1139/y80-050. [DOI] [PubMed] [Google Scholar]
  19. Viinikka L., Ylikorkala O. Measurement of thromboxane B2 in human plasma or serum by radioimmunoassay. Prostaglandins. 1980 Oct;20(4):759–766. doi: 10.1016/0090-6980(80)90114-8. [DOI] [PubMed] [Google Scholar]
  20. Whittaker N., Bunting S., Salmon J., Moncada S., Vane J. R., Johnson R. A., Morton D. R., Kinner J. H., Gorman R. R., McGuire J. C. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins. 1976 Dec;12(6):915–928. doi: 10.1016/0090-6980(76)90126-x. [DOI] [PubMed] [Google Scholar]
  21. Ylikorkala O., Kaila J., Viinikka L. Prostacyclin and thromboxane in diabetes. Br Med J (Clin Res Ed) 1981 Oct 31;283(6300):1148–1150. doi: 10.1136/bmj.283.6300.1148. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES